Venetoclax (ABT-199) is the first FDA-approved Bcl-2-specific BH3 mimetic for 17p chromosomal deletion chronic lymphocytic leukemia (CLL) patients (Zhu and Almasan, 2017). This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.